Rytelo (imetelstat) — HCPCS J0870

About Rytelo — first-in-class telomerase inhibitor FDA verified May 2026

Rytelo is not an ESA, not a luspatercept analogue, and not a hypomethylating agent.

Rytelo (imetelstat sodium) is a 13-mer oligonucleotide that binds with high affinity to the RNA template region of human telomerase, competitively inhibiting telomerase enzymatic activity. In malignant clones with high telomerase activity — including MDS clones — this telomerase inhibition impairs the proliferation of malignant cells while sparing terminal differentiation of healthy erythroid precursors. The clinical effect, established in the IMerge Phase 3 trial (NCT02598661), is sustained red-blood-cell transfusion independence in patients with lower-risk MDS who have already exhausted ESA-based options.

Rytelo was developed and is marketed by Geron Corporation. The FDA approved Rytelo on June 6, 2024 under BLA 217779 as the first telomerase inhibitor approved for any indication. It is administered intravenously over approximately 2 hours every 4 weeks, sits in the medical benefit (provider buy-and-bill), and is supplied in two single-dose lyophilized vial sizes (47 mg and 188 mg) to accommodate weight-based dosing without excessive waste. The indicated population is narrow but well-defined: adults with low- to intermediate-1 risk MDS (IPSS) or very-low, low, or intermediate-risk MDS (IPSS-R) with transfusion-dependent anemia requiring 4 or more RBC units over 8 weeks, who have not responded to, lost response to, or are ineligible for erythropoiesis-stimulating agents.

Dosing & preparation FDA label verified May 2026

7.1 mg/kg actual body weight IV over ~2 hours every 4 weeks. No BSA. Round per pharmacy SOP.

Pre-treatment workup

• IPSS-R risk calculation — requires bone marrow biopsy with cytogenetics, blast %, and cytopenia counts. Eligible: very-low, low, or intermediate-risk by IPSS-R (or low / int-1 by classic IPSS).
• Transfusion log — document ≥ 4 RBC units in the 8 weeks immediately preceding initiation. This is the IMerge eligibility threshold and the line every commercial payer enforces.
• ESA history — one of: prior ESA failure (dates, agent, duration, transfusion burden), loss of response to a previously effective ESA, or ineligibility (serum EPO > 500 mU/mL is the most defensible ineligibility marker).
• Baseline labs — CBC with differential, comprehensive metabolic panel including liver function, pregnancy test where applicable. Recheck CBC weekly through the first two cycles per label.

Reconstitution & dilution

• 47 mg vial: reconstitute with sterile water for injection per Section 2.4 of the FDA label.
• 188 mg vial: reconstitute with sterile water for injection per Section 2.4 of the FDA label.
• Final solution diluted in 0.9% sodium chloride injection prior to administration. Inspect for particulate matter; discard if cloudy or discolored.
• Single-dose vials — discard any unused portion. Plan vial selection to minimize waste (see #modifiers for vial-optimization math).
• Storage: refrigerated 2°C to 8°C in original carton; do not freeze.

Lab monitoring schedule

• Cycles 1–2: CBC with differential weekly.
• Cycles 3–6: CBC with differential before each dose.
• Cycle 7 onward: CBC with differential before each dose as clinically indicated.
• LFTs: at baseline and during therapy per clinical judgment; hold and reassess on Grade 2+ transaminase elevation.

NDC reference FDA NDC Directory verified May 2026

Administration codes CPT verified May 2026

Rytelo is a ~2-hour IV infusion. Bill 96413 for the initial hour + 96415 for each additional hour.

Modifiers & vial-waste math CMS verified May 2026

Per-mg billing. Weight-based dose almost always produces partial-vial waste. JZ + JW both common.

Worked example — 70 kg patient, 7.1 mg/kg

Common dose → unit conversion table

JZ — no waste discarded

Effective July 1, 2023, CMS requires JZ on all single-dose container claims when no drug is discarded. Pure-JZ Rytelo claims are rare because 7.1 mg/kg almost never lands cleanly on a 47 mg or 188 mg vial increment. Use JZ on the administered-units line; report any discarded units on a separate JW line.

JW — discarded portion

JW is the standard companion modifier on most Rytelo claims. The weight-based dose plus fixed vial sizes almost always produces partial-vial waste — even with optimized 188 mg + 47 mg vial mixing. Bill the administered units (e.g., 497 for the 70 kg worked example) on the JZ-style admin line and the discarded units (e.g., 20) on a separate JW line. Both lines must reflect the per-mg unit basis.

Modifier 25 — same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the infusion (common at restaging or dose-modification visits where CBC trends and response are reviewed).

340B modifiers (JG, TB)

For 340B-acquired Rytelo, follow your MAC’s current 340B modifier policy. Geron does not provide 340B-specific instructions; Rytelo is commonly carved out of 340B in heme/onc clinics due to site-of-care policies, but practice patterns vary.

ICD-10-CM by indication FY2026 verified May 2026

Use the most specific D46.x code supported by bone marrow biopsy + IPSS-R documentation.

Site of care & place of service Verified May 2026

Rytelo is a ~2-hour IV infusion with pre-medication and post-infusion observation. The clinical infrastructure required — reaction surveillance, CBC monitoring on cycle days, dose-modification decision-making — matches the hematology/oncology office, hospital outpatient department (HOPD), and ambulatory infusion center settings. Home infusion is generally not appropriate given the infusion-reaction risk profile and CBC-driven dose modifications.

Claim form field mapping Geron access guide May 2026

Standard CMS-1500 / 837P billing for outpatient IV infusion.

Payer policy snapshot Reviewed May 2026

All major commercial plans require PA. IPSS-R + transfusion burden + ESA failure documentation are universal.

Step therapy

The Rytelo FDA label itself requires a step through an ESA (failure, loss of response, or ineligibility) — this is built into the indication wording. Some BCBS and regional commercial plans add a luspatercept (Reblozyl) step on top of the label requirement, on the theory that Reblozyl is 1L for lower-risk MDS after the August 2023 COMMANDS expansion. Appeal additional steps with the FDA label language and NCCN MDS Guidelines (which list imetelstat as a category 2A option without requiring a luspatercept prerequisite).

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.

Coverage

No NCD specific to imetelstat. Coverage falls under MAC LCDs for biologics and the generic drug-coverage framework. All MACs cover J0870 for FDA-approved on-label indications with appropriate ICD-10, transfusion-dependence documentation, IPSS-R risk score, and ESA failure / ineligibility documentation. PA is not required at original Medicare but is universal at Medicare Advantage.

Code history

• J0870 — permanent code, "Injection, imetelstat, 1 mg," effective for claims with dates of service on or after the HCPCS quarterly update following FDA approval (June 2024).
• Pre-permanent-code period after June 2024 launch used unclassified J3490 / J3590 or C9399 (HOPD) with NDC documentation.
• Q2 2026 ASP+6% reflects 4Q25 submissions and applies April 1 – June 30, 2026.

Patient assistance — REACH4RYTELO Patient Support Program Geron verified May 2026

• REACH4RYTELO Patient Support Program: 1-844-RYTELO1 (1-844-798-3561), Monday–Friday 8:00 AM – 8:00 PM ET — benefits investigation, prior authorization assistance, appeals support, enrollment intake
• Enrollment: complete the Geron Patient Enrollment Form and submit by fax to 1-888-224-2518 or via the secure provider portal
• REACH4RYTELO Co-Pay Program: eligible commercially-insured patients may pay as little as $0 out-of-pocket per infusion, with a maximum benefit of $9,450 per calendar year toward drug cost and $1,200 per year toward administration (capped at $100 per infusion). Excludes Medicare, Medicaid, TRICARE, and other federal program patients.
• REACH4RYTELO Patient Assistance Program (PAP): free drug for uninsured / underinsured patients meeting income eligibility (typically ≤ 500% FPL); Geron-administered.
• Foundations (Medicare patients): PAN Foundation, HealthWell, CancerCare, Patient Advocate Foundation — verify open MDS / anemia funds quarterly. Foundation grants are the standard route for Medicare patients ineligible for the Geron copay program.
• Web: rytelohcp.com/patient-support-program · rytelo.com/patient-support

Common denials & how to fix them

Frequently asked questions

What IPSS-R risk levels qualify for Rytelo?

Rytelo is FDA-approved only for adults with low- to intermediate-1 risk MDS by IPSS (or very-low, low, or intermediate-risk by IPSS-R) with transfusion-dependent anemia. Higher-risk MDS (intermediate-2 or high by IPSS; high or very-high by IPSS-R) is outside the label. Payers will require the IPSS or IPSS-R calculation in the PA submission — include cytogenetics, blast %, and cytopenia counts so the reviewer can recompute the score.

What ESA documentation does the prior authorization require?

Payers require documentation that the patient is NOT a candidate for an ESA. Acceptable evidence falls into three buckets: (1) prior ESA trial that failed — dates, agent (epoetin alfa or darbepoetin), duration, and transfusion burden; (2) loss of response after an initial ESA response; or (3) ineligibility — serum erythropoietin level > 500 mU/mL is the most common ineligibility marker, and many plans treat serum EPO > 200 mU/mL as a soft predictor of poor ESA response per NCCN guidance. Submit the EPO lab value with the PA.

What transfusion burden threshold qualifies a patient for Rytelo?

The FDA label specifies adults requiring 4 or more red blood cell units over 8 weeks. This is the IMerge enrollment threshold and is the line every commercial payer enforces. Patients with fewer than 4 units over 8 weeks (lower transfusion burden) do not meet the label — even if other criteria are satisfied. Submit a transfusion log with dates, units, and indication for the 8 weeks preceding the PA.

How is Rytelo dosing calculated?

Rytelo is dosed at 7.1 mg/kg of actual body weight, IV over approximately 2 hours, every 4 weeks. Use actual body weight — not adjusted or ideal body weight. A 70 kg patient receives 70 × 7.1 = 497 mg per dose. There is no body-surface-area calculation and no fixed-dose option. Pre-medicate per FDA label with diphenhydramine, hydrocortisone, and an antipyretic 30–60 minutes before the infusion to mitigate infusion reactions.

What is the billable unit for HCPCS J0870?

J0870 is billed as 1 unit per 1 mg of imetelstat — the standard per-mg J-code convention. The HCPCS descriptor is "Injection, imetelstat, 1 mg." A 497 mg dose (7.1 mg/kg in a 70 kg patient) bills as 497 units administered (JZ-style line) plus any wasted units on a separate JW line. Do NOT confuse this with the 0.25 mg = 1 unit basis used by Reblozyl (J0896) — that unit basis is specific to luspatercept and does not apply to imetelstat.

What lab monitoring is required for Rytelo?

Per the FDA label, obtain a complete blood count with differential weekly for the first two cycles, before each dose for cycles 3 through 6, and before each dose as clinically indicated thereafter. The IMerge trial identified thrombocytopenia and neutropenia as the most common dose-limiting cytopenias — both require dose modifications or holds per the label. Liver function (ALT, AST, alkaline phosphatase, bilirubin) is assessed at baseline and during therapy per clinical judgment. PA renewals typically require recent CBC and response documentation (transfusion reduction).

How does Rytelo differ from Reblozyl?

Different mechanism, different unit basis, different route. Rytelo (imetelstat, J0870) is a first-in-class telomerase inhibitor given as a 2-hour IV infusion every 4 weeks, billed at 1 mg = 1 unit. Reblozyl (luspatercept-aamt, J0896) is a TGF-β superfamily ligand trap given as a subcutaneous injection every 3 weeks, billed at 0.25 mg = 1 unit. Both are positioned for lower-risk MDS transfusion-dependent anemia, but Reblozyl is approved 1L (no prior ESA required, per COMMANDS) for the full lower-risk MDS population, while Rytelo is strictly post-ESA failure or ESA-ineligible per the IMerge label.

Can Rytelo follow Reblozyl failure?

Yes — the FDA label does not exclude prior luspatercept treatment. Patients who lose response to or are intolerant of Reblozyl are commonly transitioned to Rytelo as the next line of therapy for lower-risk transfusion-dependent MDS. PA submissions should document the prior Reblozyl course (dates, doses, response or loss-of-response evidence) plus the original ESA failure or ineligibility that qualified the patient for Reblozyl in the first place. NCCN MDS guidelines list imetelstat as a category 2A option for lower-risk MDS patients no longer responding to luspatercept.

Source documents

1. Geron — RYTELO (imetelstat) Prescribing Information
   FDA-approved label (BLA 217779); initial approval June 6, 2024
2. FDA — RYTELO Highlights of Prescribing Information (June 2024)
   FDA Drugs@FDA database label PDF
3. DailyMed — RYTELO (imetelstat sodium) Prescribing Information
   NDC 82959-112-01 (47 mg) and 82959-111-01 (188 mg); current label revision
4. IMerge Phase 3 Trial — Imetelstat in Patients with Lower-Risk MDS (Lancet 2024)
   NCT02598661 — pivotal randomized trial establishing transfusion-independence benefit post-ESA
5. CMS — Medicare Part B Drug ASP Pricing File
   Q2 2026 quarterly file, effective April 1 – June 30, 2026; J0870 = $58.169/mg
6. REACH4RYTELO Patient Support Program (HCP portal)
   Geron-administered access program: benefits investigation, PA assistance, copay support, PAP
7. Aetna — Clinical Policy Bulletin 1063 (Imetelstat / Rytelo)
   Payer-side imetelstat criteria; mirrors FDA label with explicit response-based reauthorization
8. UnitedHealthcare — Medical Drug Coverage Policies (imetelstat)
9. NCCN MDS Guidelines — Imetelstat in lower-risk MDS post-ESA
   Lists imetelstat as a category 2A option for lower-risk transfusion-dependent MDS
10. FDA National Drug Code Directory
    NDC 82959-112-01 (47 mg vial) and 82959-111-01 (188 mg vial)

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 21, 2026 — Initial publication. ASP data: Q2 2026 ($58.169/mg). Manufacturer source: Geron REACH4RYTELO program materials. FDA label revision: June 6, 2024 (BLA 217779). Per-mg billing convention (1 mg = 1 unit) confirmed against HCPCS descriptor.

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer’s published medical/pharmacy policy documents. Indication list is verified against the current FDA label revision and FDA approval letters. We do not paraphrase from billing-software vendor blogs.